NIH R01 · 2025
Insurance-related barriers to medications for opioid use disorder in private and Medicaid plans
PROJECT SUMMARY In 2020, a record 71,000 opioid overdose deaths occurred in the U.S. The number of such deaths can be reduced by buprenorphine, methadone, and extended-release naltrexone, the three FDA-approved medications for opioid use disorder (MOUD). Despite this, many patients with opioid use disorder (OUD) never initiate treatment with MOUD, and those that do often drop out of treatment, increasing their risk of death. Although the uninsured are over-represented among patients with OUD, privately insured and Medicaid patients represent three-quarters of non-elderly Americans with OUD, suggesting that mitigating barriers to MOUD use in these patients is an especially important goal.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.